A Phase I, 14 Day, Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled, Repeat Dose, Ascending Cohort Study to Evaluate the Safety, Tolerability Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Normal Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 21 Dec 2016
At a glance
- Drugs GSK 3179106 (Primary)
- Indications Irritable bowel syndrome
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 16 Dec 2016 Status changed from recruiting to completed.
- 14 Jul 2016 Status changed from not yet recruiting to recruiting.
- 20 Jun 2016 New trial record